Cellectar Biosciences, Inc.
CLRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $2 | $3 | $6 |
| G&A Expenses | $0 | $4 | $3 | $7 |
| SG&A Expenses | $2 | $4 | $3 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $6 | $6 | $13 |
| Operating Income | -$5 | -$6 | -$6 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | -$0 | $10 |
| Pre-Tax Income | -$4 | -$5 | -$7 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$5 | -$7 | -$2 |
| % Margin | – | – | – | – |
| EPS | -1.41 | -3.39 | -4.3 | -1.68 |
| % Growth | 58.4% | 21.2% | -155.9% | – |
| EPS Diluted | -1.41 | -3.39 | -4.3 | -1.68 |
| Weighted Avg Shares Out | 3 | 2 | 2 | 1 |
| Weighted Avg Shares Out Dil | 3 | 2 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$6 | -$6 | -$13 |
| % Margin | – | – | – | – |